+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Comments

Loading...

Fate Therapeutics

FATENASDAQ

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$4.46

-0.09-1.98%

At Close: -

$4.55

0.092.02%

After Hours: 4:10 PM EDT

15 minutes delayed

Fate Therapeutics (FATE) Forecast

News

Earnings Guidance Dividends Analyst Ratings Insider Trades Government Trades Short Interest

Latest news for Fate Therapeutics (NASDAQ:FATE) Stock

Fate Therapeutics Stock (NASDAQ: FATE)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Tuesday, July 16, 2024

Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Avi Kapoor
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
Avi Kapoor

Wednesday, June 26, 2024

Fate Therapeutics shares are trading lower ga...
Benzinga Newsdesk

Monday, June 17, 2024

Expert Outlook: Fate Therapeutics Through The Eyes Of 9 Analysts
Benzinga Insights
This Best Buy Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Avi Kapoor
Fate Therapeutics shares are trading higher a...
Benzinga Newsdesk
Piper Sandler Upgrades Fate Therapeutics to O...
Benzinga Newsdesk

Thursday, May 16, 2024

Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday
Avi Kapoor
HC Wainwright & Co. Maintains Neutral on Fate...
Benzinga Newsdesk

Friday, May 10, 2024

Canaccord Genuity Maintains Buy on Fate Thera...
Benzinga Newsdesk
BMO Capital Maintains Market Perform on Fate ...
Benzinga Newsdesk
Wedbush Maintains Neutral on Fate Therapeutic...
Benzinga Newsdesk
Piper Sandler Maintains Neutral on Fate Thera...
Benzinga Newsdesk

Thursday, May 09, 2024

Fate Therapeutics Q1 2024 GAAP EPS $(0.47), I...
Benzinga Newsdesk
Fate Therapeutics Treats First Lupus Patient ...
Benzinga Newsdesk

Monday, May 06, 2024

Forecasting The Future: 8 Analyst Projections For Fate Therapeutics
Benzinga Insights
Wedbush Reiterates Neutral on Fate Therapeuti...
Benzinga Newsdesk

Friday, May 03, 2024

Fate Therapeutics Announces Presentation Of F...
Benzinga Newsdesk

Tuesday, April 23, 2024

Wedbush Reiterates Neutral on Fate Therapeuti...
Benzinga Newsdesk

Monday, April 22, 2024

Fate Therapeutics To Present FT819 Proof-Of-C...
Benzinga Newsdesk

Thursday, April 11, 2024

Where Fate Therapeutics Stands With Analysts
Benzinga Insights
Needham Reiterates Hold on Fate Therapeutics
Benzinga Newsdesk

Wednesday, April 10, 2024

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights

Thursday, March 28, 2024

B of A Securities Maintains Underperform on F...
Benzinga Newsdesk

Tuesday, March 19, 2024

Fate Therapeutics Announces Pricing Of $100M ...
Benzinga Newsdesk
Evaluating Fate Therapeutics: Insights From 5 Financial Analysts
Benzinga Insights
HC Wainwright & Co. Reiterates Neutral on Fat...
Benzinga Newsdesk

Tuesday, February 27, 2024

Cracking The Code: Understanding Analyst Reviews For Fate Therapeutics
Benzinga Insights
Barclays Maintains Overweight on Fate Therape...
Benzinga Newsdesk
Domino's To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Avi Kapoor
Wedbush Maintains Neutral on Fate Therapeutic...
Benzinga Newsdesk
Oppenheimer Reiterates Perform on Fate Therap...
Benzinga Newsdesk

Monday, February 26, 2024

Recap: Fate Therapeutics Q4 Earnings
Benzinga Insights
Fate Therapeutics Q4 2023 GAAP EPS $(0.45) Be...
Benzinga Newsdesk
Earnings Scheduled For February 26, 2024
Benzinga Insights

Friday, February 23, 2024

A Preview Of Fate Therapeutics's Earnings
Benzinga Insights

Monday, January 08, 2024

Fate Therapeutics shares are trading higher a...
Benzinga Newsdesk
Fate Therapeutics Announces Initiation Of Pha...
Benzinga Newsdesk

Wednesday, January 03, 2024

Pinstripes, SoFi Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Avi Kapoor

Tuesday, December 12, 2023

12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights

Monday, November 20, 2023

Mizuho Maintains Buy on Fate Therapeutics, Lo...
Benzinga Newsdesk

Monday, November 13, 2023

Morgan Stanley Maintains Equal-Weight on Fate...
Benzinga Newsdesk

Thursday, November 09, 2023

BMO Capital Maintains Market Perform on Fate ...
Benzinga Newsdesk
Analyst Ratings for Fate Therapeutics
Benzinga Insights
Wedbush Maintains Neutral on Fate Therapeutic...
Benzinga Newsdesk
Wells Fargo Maintains Equal-Weight on Fate Th...
Benzinga Newsdesk

Wednesday, November 08, 2023

Recap: Fate Therapeutics Q3 Earnings
Benzinga Insights
Fate Therapeutics Q3 2023 Gaap EPS $(0.46) Be...
Benzinga Newsdesk
Earnings Scheduled For November 8, 2023
Benzinga Insights

Thursday, October 05, 2023

Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved